Targeting Bruton’s Tyrosine Kinase With Ibrutinib in B-Cell Malignancies

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 5, 2015, Pages 455-468

  Wang, Y ^a   Zhang, L L ^b   Champlin, R E ^b   Wang, M L ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; IBRUTINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84928627935     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/CPT.85     Document Type: Article

References (79)

1. Dal Porto, J.M., Gauld, S.B., Merrell, K.T., Mills, D., Pugh-Bernard, A.E. & Cambier, J. B cell antigen receptor signaling 101. Mol. Immunol. 41, 599–613 (2004).
2. Pierce, S.K. & Liu, W. The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat. Rev. Immunol. 10, 767–777 (2010).
3. Bruton, O.C. Agammaglobulinemia. Pediatrics 9, 722–728 (1952).
4. Vetrie, D. et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361, 226–233 (1993).
5. Gururajan, M., Jennings, C.D. & Bondada, S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J. Immunol. 176, 5715–5719 (2006).
6. Niemann, C.U. & Wiestner, A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin. Cancer Biol. 23, 410– 421 (2013).
7. Irish, J.M., Czerwinski, D.K., Nolan, G.P. & Levy, R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 108, 3135– 3142 (2006).
8. Davis, R.E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88–92 (2010).
9. Pan, Z. et al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem. 2, 58–61 (2007).
10. Honigberg, L.A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. USA 107, 13075–13080 (2010).
11. Herman, S.E. et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117, 6287–6296 (2011).
12. Ponader, S. et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119, 1182–1189 (2012).
13. Woyach, J.A. et al. Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 123, 1207–1213 (2014).
14. Herman, S.E. et al. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia 27, 2311–2321 (2013).
15. Brett, L.K. et al. Drug screening reveals that ibrutinib (PCI-32765) exhibits synergy with BCL-2 and proteasome inhibitors in models of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). ASH Annual Meeting and Exposition. Abstract #3080 (2013).
16. Portell, C.A. et al. Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist, ABT-199 (GDC-0199) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): molecular analysis reveals mechanisms of target interactions. ASH Annual Meeting and Exposition. Abstract #509 (2014).
17. Tesar, B. et al. Effect of MYD88 mutation in CLL on IRAK4 and BTK inhibition in vitro. ASH Annual Meeting and Exposition. Abstract #4132 (2013).
18. Wu, C.C.N. et al. Inhibition of Wnt signaling by dimethyl fumarate results in in vitro and in vivo clearance of chronic lymphocytic leukemia cells and has additive activity with ibrutinib. ASH Annual Meeting and Exposition. Abstract #4683 (2014).
19. Ponader, S. et al. Activity of Bruton’s tyrosine kinase (Btk) inhibitor PCI-32765 in mantle cell lymphoma (MCL) identifies Btk as a novel therapeutic target. ASH Annual Meeting and Exposition. Abstract #3688 (2011).
20. Ou, Z. et al. Single-agent Bruton’s tyrosine kinase (Btk) inhibitor and single-agent carfilzomib induce cell apoptosis, arrest cell growth and downregulate NF-Kb activity in mantle cell lymphoma. ASH Annual Meeting and Exposition. Abstract #4971 (2011).
21. Cinar, M., Hamedani, F., Mo, Z., Cinar, B., Amin, H.M. & Alkan, S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk. Res. 37, 1271–1277 (2013).
22. Ou, Z. et al. Targeting BCR activated STAT3 by ibrutinib in mantle cell lymphoma. ASH Annual Meeting and Exposition. Abstract #3079 (2013).
23. Dasmahapatra, G., Patel, H., Dent, P., Fisher, R.I., Friedberg, J. & Grant, S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br. J. Haematol. 161, 43–56 (2013).
24. Zhao, X. et al. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br. J. Haematol. (2014); e-pub ahead of print 4 October 2014.
25. Zhang, L. et al. Anti-CD20 and B-cell receptor-mediated growth inhibition and apoptosis: a preclinical study of ibrutinib and rituximab combination therapy in mantle cell lymphoma in vitro and in vivo. ASH Annual Meeting and Exposition. Abstract #1774 (2014).
26. Sahakian, E. et al. Combination of ACY1215, a selective histone deacetylase 6 (HDAC6) inhibitor with the Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, represents a novel therapeutic strategy in mantle cell lymphoma (MCL). ASH Annual Meeting and Exposition. Abstract #1660 (2012).
27. Hagiwara, K., Hiroatsu Iida, M., Miyata, Y., Naoe, T. & Nagai, H. Combination of the histone deacetylase inhibitor vorinostat with a B-cell receptor signaling inhibitor markedly decreases cyclin D1 expression in a mantle cell lymphoma cell line. ASH Annual Meeting and Exposition. Abstract #3631 (2014).
28. Tabe, Y. et al. Selective inhibitor of nuclear export selinexor (KPT-330) and BCL2 inhibitor ABT-199 enhance the anti-lymphoma effect of btk inhibitor ibrutinib in mantle cell lymphoma. ASH Annual Meeting and Exposition. Abstract #2254 (2014).
29. Zoellner, A.K. et al. Differential role of the B-cell receptor pathway in diffuse large cell B cell lymphoma: temsirolimus has additive effects in combination with the BTK inhibitor PCI-32765 and PI3K inhibitor Cal101 but antagonizes bortezomib in GCB subtype. ASH Annual Meeting and Exposition. Abstract #1664 (2011).
30. Ezell, S.A. et al. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. Oncotarget 5, 4990–5001 (2014).
31. Kuo, H.-P. et al. Combination of ibrutinib and BCL-2 or SYK inhibitors in ibrutinib resistant ABC-subtype of diffuse large B-cell lymphoma. ASH Annual Meeting and Exposition. Abstract #505 (2014).
32. Yang, Y. et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21, 723–737 (2012).
33. Mathews Griner, L.A. et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl. Acad. Sci. USA 111, 2349–2354 (2014).
34. Zheng, X., Ding, N., Song, Y., Feng, L. & Zhu, J. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. Cancer Cell Int. 14, 32 (2014).
35. Dominici, E.M. et al. Carfilzomib, a second-generation proteasome inhibitor, in combination with the Btk inhibitor ibrutinib as a novel therapeutic regimen for treating double hit DLBCL. ASH Annual Meeting and Exposition. Abstract #1834 (2013).
36. Yang, G. et al. MYD88 L265P promotes survival of Waldenstrom’s macroglobulinemia cells by activation of Bruton’s tyrosine kinase. ASH Annual Meeting and Exposition. Abstract #897 (2012).
37. Chaudhary, D. et al. Synergistic blockade of activated B cell-like DLBCL proliferation with a selective inhibitor of IRAK4 in combination with inhibition of the B-cell receptor signaling network. ASH Annual Meeting and Exposition. Abstract #3833 (2013).
38. Chitta, K.S. et al. The selective Bcl-2 inhibitor ABT-199 synergizes with BTK or proteasome inhibitors to induce potent cell death in preclinical models of bortezomib or ibrutinib-resistant Waldenstroms macroglobulinemia. ASH Annual Meeting and Exposition. Abstract #1689 (2014).
39. Tai, Y.T. et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120, 1877–1887 (2012).
40. Rushworth, S.A., Bowles, K.M., Barrera, L.N., Murray, M.Y., Zaitseva, L. & MacEwan, D.J. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-ŒB. Cell. Signal. 25, 106–112 (2013).
41. Sivina, M., Kreitman, R.J., Arons, E., Ravandi, F. & Burger, J.A. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br. J. Haematol. 166, 177–188 (2014).
42. Kim, E. et al. Activity of Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) in B-cell acute lymphoblastic leukemia (B-ALL). ASH Annual Meeting and Exposition. Abstract #2569 (2012).
43. Rushworth, S.A., Murray, M.Y., Zaitseva, L., Bowles, K.M. & MacEwan, D.J. Identification of Bruton’s tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood 123, 1229– 1238 (2014).
44. Rotin, L.E. et al. Ibrutinib sensitizes AML cells to ROS inducers via a BTK-independent mechanism. ASH Annual Meeting and Exposition. Abstract #2226 (2014).
45. Advani, R.H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31, 88–94 (2013).
46. Byrd, J.C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J Med. 369, 32–42 (2013).
47. O’Brien, S. et al. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) monotherapy demonstrates long-term safety and durability of response in chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) patients in an open-label extension study. ASH Annual Meeting and Exposition. Abstract #4163 (2013).
48. O’Brien, S. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 15, 48–58 (2014).
49. Farooqui, M. et al. Single agent ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p. ASH Annual Meeting and Exposition. Abstract #673 (2013).
50. O’Brien, S. et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 Trial. ASH Annual Meeting and Exposition. Abstract #327 (2014).
51. Byrd, J.C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J Med. 371, 213–223 (2014).
52. Brown, J.R. et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH Annual Meeting and Exposition. Abstract #3331 (2014).
53. Burger, J.A. et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 15, 1090–1099 (2014).
54. Jaglowski, S.M. et al. A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J. Clin. Oncol. 32 (suppl.), abstract 7009 (2014).
55. Sharman, J.P. et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and/or refractory CLL and MCL; results of a phase II trial. ASH Annual Meeting and Exposition. Abstract #4679 (2014).
56. Brown, J.R. et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study. ASH Annual Meeting and Exposition. Abstract #525 (2013).
57. Pollyea, D.A. et al. A dose escalation study of ibrutinib with lenalidomide for relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH Annual Meeting and Exposition. Abstract #1987 (2014).
58. Wang, M.L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507–516 (2013).
59. Wang, M. et al. Single-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase 2 study. ASH Annual Meeting and Exposition. Abstract #4453 (2014).
60. Wang, M. et al. Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy. ASH Annual Meeting and Exposition. Abstract #4471 (2014).
61. Wang, M.L. et al. Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase II clinical trial. ASH Annual Meeting and Exposition. Abstract #627 (2014).
62. Wilson, W.H. et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. ASH Annual Meeting and Exposition. Abstract #686 (2012).
63. Fowler, N.H. et al. The Bruton’s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. ASH Annual Meeting and Exposition. Abstract #156 (2012).
64. Bartlett, N.L. et al. Ibrutinib monotherapy in relapsed/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial. ASH Annual Meeting and Exposition. Abstract #800 (2014).
65. Younes, A. et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 15, 1019–1026 (2014).
66. Maddocks, K. et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood 125, 242–248 (2015).
67. Christian, B. et al. A phase I study of ibrutinib and lenalidomide in patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma. ASH Annual Meeting and Exposition. Abstract #4476 (2014).
68. Treon, S.P. et al. A prospective multicenter study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. ASH Annual Meeting and Exposition. Abstract #251 (2013).
69. Vij, R. et al. Ibrutinib, single agent or in combination with dexamethasone, in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary phase 2 results. ASH Annual Meeting and Exposition. Abstract #31 (2014).
70. Jones, J.A. et al. Preliminary safety and efficacy of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL). J. Clin. Oncol. 32, 7063 (2014).
71. Chang, B.Y. et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 122, 2412–2424 (2013).
72. Herman, S.E.M., Mustafa, R.Z., Farooqui, M. & Wiestner, A. In vivo ibrutinib abrogates BCR-dependent adhesion in tumor cells of patients with chronic lymphocytic leukemia. ASH Annual Meeting and Exposition. Abstract #1936 (2014).
73. Woyach, J.A. et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123, 1810–1817 (2014).
74. Woyach, J.A. et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286– 2294 (2014).
75. Furman, R.R. et al. Ibrutinib resistance in chronic lymphocytic leukemia. N. Engl. J. Med. 370, 2352–2354 (2014).
76. Chiron, D. et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 4, 1022–1035 (2014).
77. Woyach, J.A. et al. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: a single-center experience of 267 patients. J. Clin. Oncol. 32, 7010 (2014).
78. Balasubramanian, S. et al. Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma. ASH Annual Meeting and Exposition. Abstract #78 (2014).
79. Burger, J.A. et al. Clonal evolution in patients with chronic lymphocytic leukemia (CLL) developing resistance to BTK inhibition. ASH Annual Meeting and Exposition. Abstract #866 (2013).